Clinical Trial Update: Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Announces an open-label Phase 1/2 study of NEO-811 for locally advanced or metastatic non-resectable clear cell renal cell carcinoma, currently recruiting. Spon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma
• Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma

Drugs mentioned

• NEO-811

Snippet

Sponsor: Neomorph, Inc | Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 1 | Status: RECRUITING